Delivery Order SPE2DB22D3019-SPE2DB25FK4BZ
- Not listed
- The Defense Logistics Agency awarded a $8,920.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen (2 ml) pharmaceutical supplies with an ultimate completion date of July 21, 2025. This non-set-aside, competitively awarded contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at approximately $1 billion through December 2026. The place of performance...
- The Defense Logistics Agency awarded a $5,001.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside contract represents a delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $3,523.82 to AmerisourceBergen Drug Corp for DUPIXENT (dupilumab) 300 mg/2 mL pen injections on August 8, 2025, with an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support...
- The Defense Logistics Agency awarded a $18,121.68 delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of DUPIXENT 300 mg/2 ml pen injectable medication in 2 ml quantities. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 14, 2025. The contract is being performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, and represents a child delivery order under the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,747.93 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform at its corporate office location. This delivery order falls under the company's broader...
- The Defense Logistics Agency awarded a delivery order valued at $8,632.83 to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors (2ML). The contract, executed on August 28, 2025, with completion targeted for August 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through competitive procurement processes. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,709.46 to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pens (2 ML quantity) on August 6, 2025, with an ultimate completion date of August 7, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $39,444.01 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pens on September 8, 2025, with an ultimate completion date of September 9, 2025. DUPIXENT (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic rhinosinusitis. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors valued at $7,550.30 under a firm fixed price contract. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, and represents a non-set-aside competitive award. AmerisourceBergen will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,746.28 for DUPIXENT 200 mg/1.14 mL pen injectables on May 30, 2025, with completion scheduled for June 2, 2025. This competitively awarded, firm fixed-price contract involves no set-aside provisions and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania....
- SPE2DB22D3019Indefinite Delivery Contract
- SPE2DB22D3019-SPE2DB25FK4BZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $48,006.54 to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 mL pens on August 14, 2025, with an ultimate completion date of August 15, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive $999.99 billion pharmaceutical support vehicle valued through December 2026 that enables the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs globally. DUPIXENT (dupilumab) is a biologic therapeutic used primarily for treating moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and asthma. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen has demonstrated consistent capability to fulfill specialized pharmaceutical requirements for the Defense Health Agency and other federal healthcare systems through competitive awards. The delivery order reflects routine fulfillment under the broader pharmaceutical prime vendor contract structure, supporting the Defense Logistics Agency's mission to supply critical medications to military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $48.0k | 8/14/25 |